A Prospective, Multicenter, Observational Study of the Safety and Efficacy of Emergency Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis
A legfontosabb adatok
- Ki végzi
- Qilu Hospital of Shandong University
- Hol
- Jinan (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 35 fő, tervezett
- Kezdés
- 2025. júl. 30.
- Várható befejezés
- 2028. dec. 30.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Transcatheter aortic valve and recyclable delivery system
- A regiszteradat frissítve
- 2025. augusztus 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 70 or older with severe aortic stenosis who need an emergency valve replacement through a catheter (TAVR) with the VitaFlow Liberty valve.
- Életkor
- 70 Years and older
- Nem
- All sexes can join
- A betegség stádiuma
- Severe aortic stenosis: peak flow speed through the valve ≥4.0m/s, or mean pressure difference ≥40mmHg, or valve opening area <0.8cm2 (or area index < 0.5 cm2/m2). There must also be an emergency reason: shock, ongoing ventricular tachycardia or ventricular fibrillation, unstable chest pain or heart failure that needs a machine to support blood flow, or cardiac arrest needing resuscitation.
A részvétel fő kizáró okai
- Aortic root or blood vessel shape that does not allow the valve or device to be placed
- Blocked outflow of the left heart chamber, primary dilated cardiomyopathy, or a blood clot in the left ventricle
- Cannot take blood thinners or antiplatelet drugs, or allergy to Nitinol
- Active infection of the heart valves or other infection affecting the operation
- Severe dementia, or expected to live less than half a year
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with severe aortic stenosis diagnosed at the clinic: peak transvalvular flow velocity ≥4.0m/s, or mean transvalvular pressure difference ≥40mmHg(1 mmHg=0.133kPa), or aortic valve orifice area < <0.8cm2 (or effective aortic valve orifice area index < 0.5 cm2/m2)
- Meet one of the following emergent TAVR indications:
- Shock; 2) Combined with persistent ventricular tachycardia or ventricular fibrillation; 3) Difficulty in improving unstable angina pectoris or chronic heart failure requiring mechanical circulatory assistance with drugs; 4) Cardiopulmonary resuscitation is required for cardiac arrest; 3. Patients who can understand the purpose of the study, voluntarily participate in and sign the informed consent form, and are willing to accept the relevant examinations and clinical follow-up
Ki nem vehet részt
- Patients who are unable to receive anticoagulation or antiplatelet therapy
- Anatomic morphology or vascular diseases affecting the instrument approach
- Allergy to or resistance to Nitinol
- Active stage of infective endocarditis or other infection that the researcher believes affects the operation
- Severe disability senile dementia
- Aortic root anatomy and lesions are not suitable for prosthetic valve implantation
- Left ventricular outflow tract obstruction
- Primary dilated cardiomyopathy
- Thrombus in the left ventricle
- Patients with a life expectancy of less than half a year
- The investigator determined that the patient or family had poor compliance or declined to complete the study as required
Helyszínek itt: Kína
- Qilu Hospital of Shandong UniversityJinan, KínaContact: Chuanbao LiToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The research name of this project is: A prospective, multicenter and observational study on the safety and effectiveness of emergency transcatheter aortic valve replacement (TAVR) in the treatment of patients with severe aortic stenosis. It is a prospective, multi-center clinical study, and 35 cases are planned to be enrolled and followed up for 12 months (before discharge, 30 days, 6 months and 12 months). The research instruments used are VitaFlow Liberty® transcatheter aortic valve and recoverable delivery system. The purpose of this study is to evaluate the safety and effectiveness of emergency TAVR in patients with severe aortic stenosis. The main end point is the cumulative all-cause mortality 12 months after operation, and the secondary end points mainly include adverse cerebrovascular events (MACCE), acute renal injury, implantation rate of permanent pacemaker and valve function.
A vizsgálat csoportja
- Case
Kezelés: Transcatheter aortic valve and recyclable delivery system
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. augusztus 7.